Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 28c; reaffirms guidance
Tweet
Share
E-mailGet Alerts IONS Hot Sheet
Join SI Premium – FREE
(Updated - August 9, 2023 9:07 AM EDT)
Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.60), $0.28 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $188 million versus the consensus estimate of $140.11 million.
For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- KULR Technology Group (KULR) Misses Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
